Vigil Neuroscience, Inc. (NASDAQ:VIGL) Forecasted to Post Q2 2024 Earnings of ($0.58) Per ShareZolmax • 25 days ago
Vigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report) - HC Wainwright issued their Q2 2024 EPS estimates for shares of Vigil Neuroscience in a research note issued on Wednesday, March 27th. HC...
Share to Feed
Vigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report) - Investment analysts at HC Wainwright issued their Q1 2024 EPS estimates for Vigil Neuroscience in a report released on Wednesday, March 27th...
Vigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report) - Research analysts at Wedbush lowered their Q1 2024 EPS estimates for shares of Vigil Neuroscience in a report released on Tuesday, March...
Mizuho Securities analyst Graig Suvannavejh has reiterated their bullish stance on VIGL stock, giving a Buy rating on March 27. Graig Suvannavejh h...
Reported positive interim data from Phase 2 IGNITE proof-of-concept clinical trial evaluating iluzanebart (VGL101) for treatment of ALSP Enrollment for IGNITE trial completed with 20 patients...
Vigil Neuroscience GAAP EPS of -$0.57 in-line...
Vigil Neuroscience Inc (VIGL Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Jason Butler...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
WATERTOWN, Mass., March 20, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...